Cipla | CIPLA - Operating Profit


Cipla reported INR10.43B in Operating Profit for its fiscal quarter ending in September of 2026.





Operating Profit Change Date
Arca Biopharma USD -36.43M 2M Mar/2026
aTyr Pharma USD -104K 24K Jun/2026
Bio Path USD -297K 191K Mar/2026
Brainstorm Cell Therapeutics USD -2.05M 198K Mar/2026
Capricor Therapeutics USD -29.16M 2.87M Dec/2025
Cara Therapeutics USD -7.05M 1.11M Mar/2026
Cipla INR 10.43B 1.55B Sep/2026
Dr.Reddys Laboratories INR 12.16B 8.91B Sep/2026
Immunic USD -23.33M 2.67M Dec/2025
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sun Pharmaceuticals INR 39.07B 3.5B Sep/2026
TherapeuticsMD USD -1.18M 40K Jun/2024
UPL INR 14.93B 8.25B Sep/2026